USPTO serial 79379585
Reviewed by CopyMark Law Group
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jonathan D. Reichman, Esq.
Jonathan D. Reichman, Esq. Hunton Andrews Kurth LLP200 Park AvenueNew York, NY 10166United States| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable Computer software for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; downloadable computer software for use in the research and development of pharmaceutical preparations; downloadable computer software for use in the pharmaceutical drug development and discovery; downloadable computer software for the analysis of biological or chemical activity; downloadable computer software for the analysis of pharmaceutical properties of molecules; downloadable computer software for the identification and analysis of biological targets, networks and pathways; downloadable data processing software; downloadable computer software for creating searchable databases of information and data; downloadable computer software for data analysis, pattern discovery, contextual prediction, predictive analytics and predictive modelling; downloadable computer software for compiling and analyzing scientific, pharmaceutical and medical data; downloadable computer software for use in accessing and importing data and information; downloadable interactive databases in the fields of science, medicine and pharmaceuticals; downloadable computer software for big data analytics | ACTIVE | — |
| 042 | Pharmaceutical, and scientific research and development; medical research and development in the field of disease mechanisms, therapeutics and pharmaceuticals; scientific research and technological research services in the field of pharmaceuticals and molecular biology; research and development of pharmaceutical preparations and medicines; pharmaceutical drug development and discovery services; providing online non-downloadable software data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; providing online non-downloadable software for data analysis, pattern discovery, contextual prediction, predictive analytics and predictive modelling; providing online non-downloadable software for the analysis of pharmaceutical properties of molecules; providing online non-downloadable software for the identification and analysis of biological targets, networks and pathways; providing online non-downloadable data processing software; providing online non-downloadable software for creating searchable databases of information and data; platform as a service (PAAS) featuring computer software platforms for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; software as a service (SAAS) services featuring software for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; data mining; providing online non-downloadable software for use in accessing, importing, compiling and analyzing scientific, pharmaceutical and medical data and information; providing online non-downloadable software for big data analytics; research and development of new products; cloud computing featuring software for data compiling, accessing, importing, searching, tracking, exploration, processing, integration, and analysis in the fields of science, medicine and pharmaceuticals; providing medical and scientific research information, advisory and consultancy services in the field of pharmaceuticals and molecular biology; providing information, advisory and consultancy services regarding research and development of pharmaceutical preparations and medicines | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 24, 2025 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Jun 21, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 17, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 28, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 28, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 17, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 14, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 27, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 27, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 24, 2025 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Dec 17, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 17, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 12, 2024 | CHPN | POST PUBLICATION AMENDMENT – NOT ENTERED | — |
| Dec 5, 2024 | APET | ASSIGNED TO PETITION STAFF | — |
| Nov 6, 2024 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Oct 29, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 29, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 9, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 19, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 19, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 19, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 14, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 13, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 13, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 8, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 12, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 12, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 26, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 25, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 15, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 3, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 29, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 28, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |